This session will focus on future trends in the field of Cell and Gene Therapy and Personalized Medicine. Some of the topics to be discussed include cell therapies, genetically engineered cells, and gene editing technology. Where do we see an increase in Cell & Gene Therapy and what clinical indications? What is developing in the field of personalized medicine that will bring on improvements in Healthcare and how will these improvements affect Healthcare economics? Even with the high cost of these therapies we may see a benefit financially. This session will consist of innovators in the field of Cell and Gene Therapy. Besides short presentations it will include a lively debate as to where the field is headed.
To view Spanish or English subtitles, click the "CC" box in the video player. Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Describe new technology seen in Cell and Gene Therapy and Personalized Medicine
Discuss Product Development challenges in the field of Cell and Gene Therapy
Evaluate of Healthcare Economics of Cell and Gene Therapy
Consultant: Terumo; Scientific Advisory Board: Akron, Avectas, Immuneel, Immusoft, In8bio, Ori Biotech, Vycellix; Co-Founder and equity holder: Tmunity Therapeutics; Royalties: University of Pennsylvania/Novartis; Field of cell and gene therapy: Declaration of financial interest due to intellectual property and patents
All relevant financial relationships have been mitigated. By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
AM21-53: Future Trends in Cell & Gene Therapy: Developments in the Field of Personalized Medicine Evaluation